The presentation of pre-clinical data is a significant event for pharmaceutical companies as it provides insights into the potential efficacy and safety of their products. This could influence investor sentiment, either positively if the data is promising, or negatively if the data is not as expected. However, without specific details on the data to be presented, it's difficult to predict the direction of the impact.